Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2881 | Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening Wiki | 0.26 |
| drug2639 | Prescription Opioid Management App Wiki | 0.26 |
| drug3183 | Sputum and blood sampling Wiki | 0.26 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1666 | Inhaled Hypertonic ibuprofen Wiki | 0.26 |
| drug3596 | Urine sample Wiki | 0.26 |
| drug3307 | Surgical procedures performed under general anesthesia Wiki | 0.26 |
| drug1221 | Estrogen Therapy Wiki | 0.26 |
| drug3429 | Tests Wiki | 0.26 |
| drug1679 | Inspiratory training device Wiki | 0.26 |
| drug59 | 80 ppm Nitric Oxide delivered through LungFit Delivery System Wiki | 0.26 |
| drug1240 | Exercise physiology Wiki | 0.26 |
| drug1239 | Exercise capacity Wiki | 0.26 |
| drug302 | Arterial Blood Gas test (ABG) Wiki | 0.26 |
| drug3176 | Spartan COVID-19 System Wiki | 0.26 |
| drug1187 | End tidal breath sample Wiki | 0.26 |
| drug3185 | Sputum sample Wiki | 0.26 |
| drug18 | 150 ppm Nitric Oxide delivered through LungFit Delivery System Wiki | 0.26 |
| drug36 | 2: Usual practice + SYMBICORT RAPIHALER Wiki | 0.26 |
| drug25 | 1: Usual practice Wiki | 0.26 |
| drug1166 | Electrical Impedance Tomography (EIT) Wiki | 0.26 |
| drug566 | Bronchoalveolar Lavage (BAL) Wiki | 0.26 |
| drug247 | Angiotensin Receptor Blockers Wiki | 0.26 |
| drug1251 | Expiratory training device Wiki | 0.26 |
| drug2203 | Nitric Oxide delivered via LungFit™ system Wiki | 0.26 |
| drug1311 | Fiberoptic Bronchoscopy (FOB) Wiki | 0.26 |
| drug1909 | Lung Function tests Wiki | 0.26 |
| drug2862 | Remote Photoplethysmography (rPPG) vital sign acquisition Wiki | 0.26 |
| drug1772 | Janus Kinase Inhibitor (ruxolitinib) Wiki | 0.26 |
| drug1454 | Health-related quality of life Wiki | 0.26 |
| drug548 | Breath test Wiki | 0.26 |
| drug2702 | Pulmonary Rehabilitation Wiki | 0.26 |
| drug3040 | Sample collection Wiki | 0.18 |
| drug997 | Data collection Wiki | 0.15 |
| drug2161 | Nasopharyngeal swab Wiki | 0.12 |
| drug3993 | no intervention Wiki | 0.09 |
| drug518 | Blood sample Wiki | 0.08 |
| drug3485 | Tocilizumab Wiki | 0.04 |
| drug2505 | Placebo Wiki | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012140 | Respiratory Tract Diseases NIH | 0.83 |
| D014652 | Vascular Diseases NIH | 0.13 |
| D006331 | Heart Diseases NIH | 0.08 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.07 |
| D053120 | Respiratory Aspiration NIH | 0.07 |
| D008173 | Lung Diseases, Obstructive NIH | 0.07 |
| D011024 | Pneumonia, Viral NIH | 0.06 |
| D018352 | Coronavirus Infections NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
| D011014 | Pneumonia NIH | 0.04 |
| D003141 | Communicable Diseases NIH | 0.04 |
| D007239 | Infection NIH | 0.03 |
| D013577 | Syndrome NIH | 0.03 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0006510 | Chronic pulmonary obstruction HPO | 0.09 |
| HP:0006536 | Pulmonary obstruction HPO | 0.08 |
| HP:0002090 | Pneumonia HPO | 0.04 |
Navigate: Correlations HPO
There are 15 clinical trials
The aim of this study is to generate epidemiological data to further explore determinants of Chronic Obstructive Pulmonary Disease (COPD) and the contribution of bacterial and viral pathogens to Acute Exacerbation of COPD (AECOPD) episodes.
Description: An Acute Exacerbation in a COPD patient is an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough, and/or sputum production and beyond normal day to day variations, that is acute in onset and may warrant a change in regular medication in a patient with underlying COPD The Means and Confidence Intervals (CI) were estimated using the Negative Binomial model taking into account time to follow up. Estimated exacerbations were presented as mean number of exacerbations per (/) subject/ year.
Measure: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) Time: During year 1Description: Bacterial pathogens assessed were: Haemophilus influenzae (Hi), Moraxella catarrhalis (Mcat), Steptococcus pneumoniae (Sp), Staphylococcus Aureus (Sta), Pseudomonas aeruginosa (Psa), any or other. For each bacteria, the means and CIs were estimated from Negative Binomial model taking into account the follow up time.Estimated exacerbations were presented as mean number of exacerbations/ subject/ year.
Measure: Mean Estimated Number of AECOPD With Sputum Containing Bacterial Pathogens Time: During Year 1Description: Bacterial pathogens assessed, by culture, were: Haemophilus influenzae (Hi), Moraxella catarrhalis (Mcat), Streptococcus pneumoniae (Sp), Staphylococcus aureus (Sta), Pseudomonas aeruginosa (Psa), any bacteria or other bacteria. Overall exacerbation rate is the average number of exacerbations for each subject during their time in the study.
Measure: Overall AECOPD Exacerbation Rate for Any and Specific Bacterial Pathogens in Sputum Time: During Year 1Description: Sputum samples were tested by bacterial species (any bacteria, Hi, Mcat, Sp, Sta, Psa and other bacteria), or overall and were obtained from culture at each visit (enrollment, any stable visit, any exacerbation visit, any mild exacerbation visit, any moderate exacerbation visit, any severe exacerbation visit). This endpoint presents results for any bacteria and Hi.
Measure: Number of Sputum Samples Positive for Specific Pathogens - Any Bacteria and Hi Time: During Year 1Description: Sputum samples were tested by bacterial species (any bacteria, Hi, Mcat, Sp, Sta, Psa and other bacteria), or overall and were obtained from culture at each visit (enrollment, any stable visit, any exacerbation visit, any mild exacerbation visit, any moderate exacerbation visit, any severe exacerbation visit). This endpoint presents results for Mcat and Sp.
Measure: Number of Sputum Samples Positive for Specific Pathogens - Mcat and Sp Time: During Year 1Description: Sputum samples were tested by bacterial species (any bacteria, Hi, Mcat, Sp, Sta, Psa and other bacteria), or overall and were obtained from culture at each visit (enrollment, any stable visit, any exacerbation visit, any mild exacerbation visit, any moderate exacerbation visit, any severe exacerbation visit). This endpoint presents results for Sta, Psa and other bacteria.
Measure: Number of Sputum Samples Positive for Specific Pathogens - Sta, Psa and Other Bacteria Time: During Year 1Description: The number of days between 2 consecutive exacerbations, as estimated by the investigator, was calculated only whenever the first exacerbation had an end date.
Measure: Mean Number of Days Between 2 Consecutive AECOPDs Time: During Year 1Description: The exacerbations of chronic pulmonary disease tool version 1.0 (EXACT) is a validated self-administered instrument that evaluates the effects of pharmacologic treatment on acute exacerbations of COPD. Analyses of exacerbations in relation to morning or evening EXACT-PRO e-diaries were presented as follows: descriptive statistics on the EXACT daily scores tabulated at enrolment, at any stable and at any, mild, moderate or severe exacerbation visit. EXACT-PRO contains 14 questions with scores ranging from 0 to 4, where 0= best outcome while 4= worse outcome.
Measure: Change From Baseline EXAcerbations of Chronic Pulmonary Disease Tool (EXACT) Scores at Enrollment and Any AECOPD Visit Time: During Year 1Description: The COPD assessment test (CAT) is a validated self-administered instrument designed to provide a simple and reliable measure of health status in COPD patients. Its properties have been shown to be similar to the St George's respiratory questionnaire (SGRQ). The CAT comprises 8 items and has a scoring range of 0-40, 0= most positive answer and 40= most negative answer. In this study, the subjects were to complete the CAT questionnaire every 3 months.
Measure: Change From Baseline COPD Assessment Test (CAT) Scores at Enrollment and Any AECOPD Visit Time: During Year 1Description: The NEADL assessed (quarterly in the present study) the ease or difficulty in performing extended activities of daily living. The NEADL scale contains 22 items, each measured on a 4-point Likert scale. There are four dimensions: mobility (6 items); kitchen (5 items); domestic (5 items); leisure (6 items). These are summed producing a total score reflecting general functioning. Each of the 22 individual items had 2 possible scores (0 or 1). Therefore, the range of the NEADL score was 0 to 22. Lower scores indicate greater levels of disability while higher scores indicate greater independence.
Measure: Change From Baseline COPD Nottingham Extended Activities of Daily Living Scale (NEADL) Scores at Enrollment and Any AECOPD Visit Time: During Year 1Description: The EQ-5D is an established measure of generic health outcome that provides a simple descriptive profile and a single index value that can be used in clinical and economic evaluation of healthcare and in population surveys. Its current format is 3-level and 5 dimensional (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The EQ-5D index was derived from the ratings recorded every 3 months for each of the five individual items (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The EQ-5D index was 0 (worst health state) to 100 (best health state). The negative numbers presented represent a decrease from baseline values and a worsening of health.
Measure: Change From Baseline COPD EQ-5D Index and Visual Analogue Scale (VAS) Scores at Enrollment and Any AECOPD Visit Time: During Year 1Description: AECOPD health care type included: general practitioners (other than the study doctor), pneumologists, other specialists, hospital emergency department, home care nurses, pulmonary rehabilitation programs and/or nutrition advices.
Measure: Number of Subjects Receiving Various Health Care Types During AECOPD Time: During Year 1Description: Serious adverse events (SAEs) include medical occur-rences that result in death, are life threatening, require hospitali-zation or prolongation of hospitalization or result in disabil-ity/incapacity.
Measure: Number of Subjects With Serious Adverse Events (SAEs) Possibly Related/Linked to Withdrawal Time: During Year 1Description: Bacterial pathogens assessed, by PCR assay were: Hi, Mcat, Sp, Sta, Psa, Streptococcus pyogenes (Spyo) and any bacteria.
Measure: AECOPD Rate With Overall and Specific Bacterial Pathogens in Sputum , by Polymerase Chain Reaction (PCR) Assay Time: During Year 1Description: Viral pathogens assessed were: respiratory syncytial virus (RSV), parainfluenza virus (PIV), entero rhinovirus (ENV), human metapneumovirus (HMP), influenza virus (INV), adenovirus (ADV), coronavirus (CRV), human bocavirus (HBoV) and any virus.
Measure: AECOPD Rate With Overall and Specific Viral Pathogens in Sputum Time: During Year 1Description: Viral pathogens assessed were: respiratory syncytial virus (RSV), parainfluenza virus (PIV), entero rhinovirus (ENV), human metapneumovirus (HMP), influenza virus (INV), adenovirus (ADV), coronavirus (CRV), human bocavirus (HBoV) and any virus. Mild exacerbations were defined as worsening symptoms of COPD that were self-managed by the patient.
Measure: Mild-AECOPD Rate With Overall and Specific Viral Pathogens in Sputum Time: During Year 1Description: Viral pathogens assessed were: respiratory syncytial virus (RSV), parainfluenza virus (PIV), entero rhinovirus (ENV), human metapneumovirus (HMP), influenza virus (INV), adenovirus (ADV), coronavirus (CRV), human bocavirus (HBoV) and any virus. Moderate exacerbations were defined as worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics.
Measure: Moderate-AECOPD Rate With Overall and Specific Viral Pathogens in Sputum Time: During Year 1Description: Viral pathogens assessed were: respiratory syncytial virus (RSV), parainfluenza virus (PIV), entero rhinovirus (ENV), human metapneumovirus (HMP), influenza virus (INV), adenovirus (ADV), coronavirus (CRV), human bocavirus (HBoV) and any virus. Severe exacerbations were defined as worsening symptoms of COPD that required treatment with in-patient hospitalisation or home care intervention.
Measure: Severe-AECOPD Rate With Overall and Specific Viral Pathogens in Sputum Time: During Year 1Description: An Acute Exacerbation in a COPD patient is an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough, and/or sputum production and beyond normal day to day variations, that is acute in onset and may warrant a change in regular medication in a patient with underlying COPD. AECOPD severity was assessed as: any, mild, moderate and severe. Any = any COPD symptom regardless of severity. Mild = Worsening symptoms of COPD that are self-managed by the patient. Moderate = Worsening symptoms of COPD that require treatment with oral corticosteroids and/or antibiotics. Severe = Worsening symptoms of COPD that require treatment with in-patient hospitalisation or home care intervention.
Measure: AECOPD Rate With Overall and Specific Bacterial Pathogens in Sputum by Severity Time: During Year 1Since the infectious aetiology of AECOPD has been suggested to vary according to geographical region, the primary purpose of this study (which will be conducted in several countries in Asia Pacific) is to evaluate the occurrence of bacterial and viral pathogens in the sputum of stable COPD patients and at the time of AECOPD. Given the increasing and projected burden of COPD in the Asia Pacific region, this study will also evaluate the frequency, severity and duration of AECOPD, as well as the impact of AECOPD on health-related quality of life (HRQOL), healthcare utilisation and lung function.
Description: Bacterial pathogens, as identified by bacteriological methods, including (but not necessarily limited to) Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii.
Measure: Occurrence of potential bacterial in sputum of stable COPD patients. Time: Over the course of 1 yearDescription: Bacterial pathogens, as identified by bacteriological methods, including (but not necessarily limited to) Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii.
Measure: Occurrence of potential bacterial in sputum during AECOPD. Time: Over the course of 1 yearDescription: Viral pathogens, as identified by PCR, including (but not necessarily limited to) Respiratory syncytial virus (RSV), parainfluenza virus, enterovirus/ rhinovirus, metapneumovirus, influenza virus, adenovirus, bocavirus and coronavirus and by rhinovirus quantitative RT-PCR.
Measure: Occurrence of viral pathogens in sputum of stable COPD patients. Time: Over the course of 1 yearDescription: Viral pathogens, as identified by PCR, including (but not necessarily limited to) Respiratory syncytial virus (RSV), parainfluenza virus, enterovirus/ rhinovirus, metapneumovirus, influenza virus, adenovirus, bocavirus and coronavirus and by rhinovirus quantitative RT-PCR.
Measure: Occurrence of viral pathogens in sputum during AECOPD. Time: Over the course of 1 yearDescription: Including (but not necessarily limited to) H. influenzae, M. catarrhalis, S. pneumoniae, S. aureus and P. aeruginosa. The proportion of sputum samples obtained at each confirmed stable/AECOPD visit and positive for specific bacterial pathogens by PCR will be computed with 95% confidence intervals.
Measure: Occurrence of potential bacterial pathogens in sputum of stable COPD patients and during AECOPD, as measured by real-time qualitative PCR/ quantitative PCR and compared to data from bacteriological methods. Time: Over the course of 1 yearDescription: The proportion of sputum samples obtained at each AECOPD visit and positive for specific bacterial/viral pathogens by bacteriological methods and PCR, respectively (overall and by bacterial/viral species) will be computed with 95% confidence intervals by any severity (mild, moderate and severe).
Measure: Occurrence of potential bacterial and viral pathogens (overall and by species) in sputum during AECOPD by severity of AECOPD. Time: Over the course of 1 yearDescription: The proportion of sputum samples obtained at each confirmed stable visit and positive for bacterial/viral pathogens by bacteriological methods and PCR, respectively (overall and by bacterial / viral species) will be computed with 95% confidence intervals by Gold grade at enrolment.
Measure: Occurrence of potential bacterial and viral pathogens (overall and by species) in sputum of stable COPD patients by GOLD grade. Time: Over the course of 1 yearDescription: The following incidence rates will be computed, with 95% confidence intervals (CI): All-cause AECOPD. AECOPD having sputum containing bacterial pathogens found by PCR or by bacteriological methods or by both methods (overall and by, but not limited to, the following bacterial species: H. influenzae, M. catarrhalis, S. pneumoniae, S. aureus, and P. aeruginosa). The 95% CI of the incidence rate will be computed using a model which accounts for repeated events. The incidence rates described above will also be computed for mild, moderate severe AECOPD and by GOLD grade at enrolment.
Measure: Incident rate (per subject per year) of any AECOPD overall and by GOLD grade. Time: Over the course of 1 yearDescription: Classification of severity according to the intensity of medical intervention required: mild: controlled with an increase in dosage of regular medications; moderate: requires treatment with systemic corticosteroids and/ or antibiotics; severe: requires hospitalisation.
Measure: Number of mild, moderate or severe AECOPD overall and by GOLD grade. Time: Over the course of 1 yearDescription: Descriptive statistics (median, mean, range, standard deviation, first and third quartiles) on the number of days of AECOPD episodes will be presented.
Measure: Number of days of AECOPD episodes overall and by AECOPD severity. Time: Over the course of 1 yearDescription: Descriptive statistics (median, mean, range, standard deviation, first and third quartiles) on the CAT scores will be tabulated at each respective visit.
Measure: COPD assessment test (CAT) score in stable COPD patients and during AECOPD. Time: Over the course of 1 yearDescription: Descriptive statistics (median, mean, range, standard deviation, first and third quartiles) on the SGRQ-C scores will be tabulated at each respective visit.
Measure: St. George's Respiratory Questionnaire (SGRQ-C) score in stable COPD patients. Time: Over the course of 1 yearDescription: The spirometric classification of airflow limitation in COPD patients is based on post-bronchodilator FEV1. Summary statistics (mean, median, standard deviation, maximum and minimum) on post bronchodilator FEV1% of predicted normal value will be tabulated at each respective visit.
Measure: Forced expiratory volume in 1 second (FEV1%) of predicted normal value in stable COPD patients. Time: At Pre-Month 0 and Month 12Description: Healthcare use for each COPD patient will be obtained through review of the subject's medical record (aided by subject self-reporting). Healthcare utilisation includes all unscheduled visits to a physician office, visits to urgent care, visits to emergency department, and hospitalizations.
Measure: Assessment of the Healthcare utilization. Time: Over the course of 1 yearA randomized controlled clinical trial will be carried out using inspiratory and expiratory training devices on healthy subjects recruited in social networks and university environments. The aim will be to determine the effectiveness and safety in the prevention and severity of COVID-19 disease by a respiratory training with inspiratory and expiratory devices.
Description: Dichotomous categorical variable measured by "yes" or "no" responses
Measure: COVID-19 disease diagnosis Time: Change from Baseline COVID-19 disease diagnosis at 8 weeksDescription: Dichotomous categorical variable measured by "slight" or "severe" responses
Measure: COVID-19 disease symptoms severity Time: Change from Baseline COVID-19 disease symptoms severity at 8 weeksDescription: Polytomous categorical variable measured by adverse effects responses
Measure: Adverse effects Time: Change from Baseline adverse effects at 8 weeksOn Dec 31, 2019, a number of viral pneumonia cases were reported in China. The virus causing pneumonia was then identified as a new coronavirus called SARS-CoV-2. Since this time, the infection called coronavirus disease 2019 (COVID-19) has spread around the world, causing huge stress for health care systems. To diagnose this infection, throat and nose swabs are taken. Unfortunately, the results often take more than 24 hrs to return from a laboratory. Speeding diagnosis up would be of great help. This study aims to look at the breath to find signs that might allow clinicians to diagnose the coronavirus infection at the bedside, without needing to send samples to the laboratory. To do this, the team will be using a machine called a BreathSpec which has been adapted to fit in the hospital for this purpose.
Description: breath sample collection
Measure: To perform a study in patients with clinical features of pneumonia/chest infection to identify a signature of Covid-19 pneumonia in patients exposed to SARS-CoV-2, compared to unexposed patients or those without. Time: up to daily during hospital admissionDescription: breath sample collection
Measure: Detection of markers of Covid-19 pneumonia in non-invasive breath samples. Time: multiple samples up to 60 daysDescription: breath sample collection
Measure: Relationship of this biomarker signature to the presence of SARS-CoV-2 in nasal and throat swabs. Time: multiple samples up to 60 daysDescription: breath sample collection
Measure: Subsequently, the signature's relationship to other biomarkers of SARS-CoV-2 infection which are currently being explored Time: multiple samples up to 60 daysDescription: breath sample collection
Measure: In a smaller group of participants, ideally daily non-invasive breath samples will be collected to determine if there are changes between SARS-CoV-2 positive patients and those that are negative until hospital discharge or undue participant burden . Time: multiple samples up to 60 daysWe hypothesize that inhaled steroid therapy and long acting beta 2 adrenergic agonist, widely prescribed in asthma patients, may also have a local protective effect against coronavirus infection, even in patients without asthma. The primary purpose is To compare time to clinical improvement in patients receiving standard of care associated to the combination budesonide/formoterol or standard of care only. Time (in days) to clinical improvement is defined as the time from randomization to an improvement of two points (from the status at randomization) on a seven-category ordinal scale or live discharge from the hospital, whichever came first within 30 days.
Description: Time (in days) to clinical improvement is defined as the time from randomization to an improvement of two points (from the status at randomization) on a seven-category ordinal scale or live discharge from the hospital, whichever came first within 30 days. The seven-category ordinal scale consisted of the following categories: Not hospitalized with resumption of normal activities Not hospitalized, but unable to resume normal activities Hospitalized, not requiring supplemental oxygen Hospitalized, requiring supplemental oxygen Hospitalized, requiring nasal high-flow oxygen therapy, non-invasive mechanical ventilation, or both; Hospitalized, requiring ECMO, invasive mechanical ventilation, or both Death. These parameters will be evaluated daily during hospitalization.
Measure: Time (in days) to clinical improvement within 30 days after randomization Time: within 30 daysProspective cohort study of COVID-19 infection among children in Norway.
Description: Identify comorbidities predisposing for severe infection
Measure: Risk Factors for severe infection Time: 2030Description: Immunological response to acute infection, focusing on initial innate host response and its associations to inflammatory enhancement, genetic factors and clinical course.
Measure: Immunulogical mechanisms Time: 2030Description: prevalence and risk factors of long-lasting complication, in particular the development of post-infectious chronic fatigue
Measure: Long term outcome Time: 2030The study aims to evaluate the reduction in severity and progression of lung injury with inhaled ibuprofen in patients with severe acute respiratory syndrome due to SARS-CoV-2 virus.
Description: Time to clinical improvement: defined as time from inhaled Ibuprofen first dose to an improvement of three points from the status on a seven-category ordinary scale
Measure: Change in the scale of ordinary COVID results at 7, 14 and 28 days in patients with acute respiratory infection, induced by SARS-CoV-2, treated with inhaled Ibuprofen. Time: 7, 14 and 28 daysDescription: Negativization of two consecutive pharyngo-nasal swab 24-72 hrs apart
Measure: Change to Negativization of the swab to the following treatment points on day 7, day 14, 21 and 28 after treatment with inhaled Ibuprofen. Time: 7, 14 and 28 daysDescription: NEWS2 score 20 points is the maximum and indicates that the patient needs emergent assessment by a clinical team or critical care team and usually transfer to higher level of care.
Measure: Average score of National Early Warning (NEWS2) between days 1, 7, 14 and 28. Time: 1, 7, 14 and 28Description: qSOFA, score for sepsis, a maximum value of 3 indicates high risk qSOFA Scores 2-3 are associated with a 3- to 14-fold increase in in-hospital mortality. Assess for evidence of organ dysfunction with blood testing including serum lactate and calculation of the full SOFA Score. Patients meeting these qSOFA criteria should have infection considered even if it was previously not.
Measure: Average change in quick sepsis-related organ failure assessment score (qSOFA) score between day 1, 7, 14 and 28. Time: 1, 7, 14 and 28 daysThis study applied the Pulmonary Rehabilitation Adapted Index of Self-Efficacy (PRAISE) on respiratory patients who had their on-going ambulatory Pulmonary Rehabilitation program interrupted due to the COVID-19 outbreak. The research hypothesis is that ranking patients' self-efficacy is a useful screening tool to support patients' follow-up on a Pulmonary Rehabilitation telehealth solution to be explored during the COVID-19 outbreak.
Description: Vincent and co-authors (2011) proposed the Pulmonary Rehabilitation Adapted Index of Self-Efficacy (PRAISE). The PRAISE tool is composed by a total of 15 items, combining 10 items from the General Self-Efficacy Scale (GSE) by Schwarzer and Jerusalem (1995), and 5 new specific items related to Pulmonary Rehabilitation. Each item is scored from 1 to 4 with a total range from 15 to 60, with higher scores indicating higher levels of self-efficacy. This study applies the Portuguese PRAISE version by Santos CD and co-authors (2019).
Measure: Patient's self-efficacy Time: 3 daysDescription: Patients were questioned if they were engaging on a daily routine of respiratory exercises by their initiative while isolated at home COVID-19 outbreak. The answer was registered as yes/no.
Measure: Respiratory exercises Time: 3 daysDescription: Patients were questioned if they managed to preserve a daily period to practice physical activity while isolated at home during COVID-19 outbreak. The answer was recorded as yes/no. In case of a positive answer, information concerning available equipment and exercise protocol adopted at patient's home environment was also collected.
Measure: Physical activity Time: 3 daysDescription: Number of Pulmonary Rehabilitation hospital sessions completed as outpatient, according to Hospital Pulido Valente information system
Measure: Treatment sessions completed Time: 3 daysDescription: Number of Pulmonary Rehabilitation sessions planned per week, according to Hospital Pulido Valente information system
Measure: Treatment weekly frequency Time: 3 daysThe Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY) study is a pragmatic prospective, open-label, randomised controlled trial. CLARITY aims to examine the effectiveness of angiotensin II receptor blockers (ARBs) on improving the outcomes of people who tested positive for COVID-19 disease.
Description: To determine whether the addition of the intervention, compared to standard care, changes the clinical health score of a participant on the following scale; Not hospitalized, no limitations on activities. Not hospitalized, limitation on activities; Hospitalized, not requiring supplemental oxygen; Hospitalized, requiring supplemental oxygen; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); Death;
Measure: 7-Point National Institute of Health Clinical Health Score Time: 28 DaysDescription: To determine whether the addition of the intervention, compared to standard care, changes the clinical health score of a participant on the following scale; Not hospitalized, no limitations on activities. Not hospitalized, limitation on activities; Hospitalized, not requiring supplemental oxygen; Hospitalized, requiring supplemental oxygen; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); Death;
Measure: 7-Point National Institute of Health Clinical Health Score Time: 15 DaysDescription: To determine whether the addition of the intervention, compared to standard care, changes the risk of all cause mortality
Measure: Mortality Time: 28 DaysDescription: To determine whether the addition of the intervention, compared to standard care, changes the risk of all cause mortality
Measure: Mortality Time: 90 DaysDescription: To determine whether the addition of the intervention, compared to standard care, changes the count of all cause Intensive Care Unit admission
Measure: Intensive Care Unit Admission Time: 28 DaysDescription: To determine whether the addition of the intervention, compared to standard care, changes the count of all cause Intensive Care Unit admission
Measure: Intensive Care Unit Admission Time: 90 DaysDescription: To determine whether the addition of the intervention, compared to standard care, changes the number of days total, of intensive care unit admission
Measure: Intensive Care Unit Admission Time: 90 DaysDescription: To determine whether the addition of the intervention, compared to standard care, changes the incidence of respiratory failure
Measure: Respiratory Failure Time: 90 DaysDescription: To determine whether the addition of the intervention, compared to standard care, changes the requirements for dialysis
Measure: Dialysis Requirement Time: 90 DaysDescription: To determine whether the addition of the intervention, compared to standard care, changes the number of hospitalisation days
Measure: Hospitalisation Days Time: 28 DaysDescription: To determine whether the addition of the intervention, compared to standard care, changes the number of hospitalisation days
Measure: Hospitalisation Days Time: 90 DaysDescription: To determine whether the addition of the intervention, compared to standard care, changes need for ventilation
Measure: Ventilator-Free Days Time: 28 DaysDescription: To determine whether the addition of the intervention, compared to standard care, changes need for dialysis
Measure: Dialysis Days Time: 28 DaysDescription: To determine whether the addition of the intervention, compared to standard care, changes risk of acute kidney injury, based on the idney Disease: Improving Global Outcomes definition
Measure: Acute Kidney Injury Time: 28 DaysDescription: To determine whether the addition of the intervention, compared to standard care, changes risk of hypotension requiring vasopressors
Measure: Hypotension Requiring Vasopressors Time: 90 DaysThe purpose of this open label, randomized, study is to obtain information on the safety and efficacy of 80 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by SARS-CoV-2.
Description: Time to deterioration measured by need for NIV, HFNC or intubation
Measure: Time to deterioration Time: 14 DaysDescription: Time to non-invasive ventilation
Measure: Time to NIV Time: 14 DaysDescription: Time to high flow nasal cannula
Measure: Time to HFNC Time: 14 DaysDescription: Time to intubation
Measure: Time to intubation Time: 14 daysDescription: Time to patient having stable oxygen saturation (SpO2) of greater than or equal to 93%
Measure: Time to patient having stable oxygen saturation (SpO2) of greater than or equal to 93% Time: 14 daysDescription: Need for supplemental oxygen
Measure: Need for supplemental oxygen Time: 14 daysDescription: Change in viral load
Measure: Change in viral load Time: 30 daysDescription: Duration of the Hospital Length of Stay (LOS)
Measure: Duration of the Hospital Length of Stay (LOS) Time: 14 daysDescription: Mortality rate at Day 30
Measure: Mortality rate at Day 30 Time: 30 daysA new Coronavirus (SARS-CoV-2) emerged in Wuhan Province, China in December 2019 and rapidly spread around the world. To date, the data in the literature regarding the clinical and epidemiological characteristics of severe forms of CoVid-19 in patients with chronic respiratory disease are not well known. The hypothesis is that patients with chronic respiratory disease (COPD, asthma, bronchial dilatations, pulmonary hypertension, cystic fibrosis, obesity-hypoventilation syndrome, obstructive sleep apnea syndrome) infected with SARS-Cov-2 will have increased dyspnea and hypoxemia leading to hospitalization for severe forms more frequently than the general population. However, they do not appear to be more at risk of developing a critical form. This study is carried out in order to propose to estimate the prevalence of critical forms of CoVid19 among patients with chronic respiratory diseases hospitalized for severe forms.
Description: Value of 6 or greeter on WHO CoVid-19 scale, indicating of a critical form of CoVid-19.
Measure: Percentage of patients who reached, during their hospitalization, a value greater than or equal to 6 on the WHO CoVid-19 infection progression scale Time: up to 28 days (during hospitalisation)Description: Radiological damage (extension of ground-glass) could be a predictive factor.
Measure: Determined potential predictive factors of critic form in patients with chronic lung diseases Time: up to 28 days (during hospitalisation)Description: intra-hospital death, intra-ICU death
Measure: Determined percentage of death Time: up to 28 days (during hospitalisation)Description: in days (or duration at a different flow rate compared to long-term home oxygen therapy prior to hospitalization)
Measure: Determined duration of oxygen therapy Time: up to 28 days (during hospitalisation)Description: in days for patients with chronic respiratory disease between the date of admission and the date of discharge. Patients who died during hospitalization will be assigned the highest cohort value.
Measure: Determined duration of hospitalization Time: up to 28 days (during hospitalisation)Description: values will be measured at D3, D7 and D14 in each of the groups. Patients who do not reach D7 and D14 will have the last postponement
Measure: Determine mean values of the WHO CoVid-19 infection progression scale measured Time: up to 28 days (during hospitalisation)The purpose of this open label, 2-phase, study is to obtain information on the safety of 80 ppm and the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by SARS-CoV-2.
Description: Time to deterioration as measured by any one of the following: need for non-invasive ventilation need for high flow nasal cannula (HFNC) or need for intubation Death from any cause
Measure: Time to deterioration Time: up to 14 daysDescription: Time to patient having stable oxygen saturation (SpO2) of greater than 92% for longer than 3 hr on room air
Measure: Time to stable oxygen saturation Time: up to 14 daysDescription: Treatment Emergent Adverse Events and SAEs - safety evaluation for 30 days after last inhalation treatment
Measure: Treatment Emergent Adverse Events and SAEs Time: 30 days after last inhalation treatmentThe COVID-19 pandemic has had a dramatic effect in public health worldwide. In Brazil, there have been more than 2 million confirmed cases and over 75,000 deaths since February 26, 2020. Based on reports of a hyperinflammatory state associated with COVID-19, the use of immunosuppressive drugs may be efficacious in the treatment of this disease. JAK inhibitors have been shown to harness inflammation in a number of different pathologic conditions. The aim of the present study is to evaluate the efficacy and safety of JAK inhibitor ruxolitinib in patients with acute respiratory distress syndrome due to COVID-19.
Description: ICU admission, mechanical ventilation, death or consent withdrawal
Measure: Time to treatment failure Time: 28 daysContactless and widely available health monitoring technologies are of growing interest in the context of the worldwide COVID-19 pandemic. Remote photoplethysmography (rPPG) is a well-studied technology that interprets variations in skin colour related to blood flow which, when analysed with complex mathematical algorithm, generates vital sign readings. This technology has been refined and embedded in a smartphone app designed to acquire heart rate, respiratory rate and oxygen saturation using a front-facing smartphone camera. Preliminary data comparing the accuracy of smartphone rPPG readings with conventional vital sign monitor readings are promising; however, less than 5% of the population studied in the app development phase had oxygen saturation levels below 95% making it impossible to ensure reliability in these populations. The goal of this study is to compare readings acquired using this rPPG app with the readings from hospital grade, Health Canada approved vital signs monitors used in healthcare settings with a focus on subject with low oxygen saturations. We will also study other sociodemographic and clinical features that may influence the accuracy of the readings. This will be achieved by recruiting consenting adults presenting to care in acute care settings and a designated COVID outpatient clinic. Vital signs will be acquired using the rPPG app and conventional hospital vital sign monitors simultaneously. Readings will be repeated within 2-5 minutes when time permits. Statistical analysis will be performed to analyze the findings and determine the accuracy and precision of the rPPG app readings. It is expected that the vital sign readings acquired with the rPPG app will be almost identical to those acquired using hospital-grade monitors for all subjects regardless of age, gender, skin colour, COVID status and relevant comorbidities.
Description: Accuracy of rPPG heart rate compared to conventional vital sign monitor heart rate readings. Comparison of each paired reading.
Measure: Accuracy of rPPG heart rate Time: immediate; paired readingDescription: Accuracy of rPPG oxygen saturation compared to conventional vital sign monitor oxygen saturation readings. Comparison of discrepancy within each paired reading set.
Measure: Accuracy of rPPG oxygen saturation Time: immediate; paired readingDescription: Accuracy of rPPG respiratory rate compared to manual counting of respiratory rate over 60 seconds. Comparison of discrepancy within each paired reading set.
Measure: Accuracy of rPPG respiratory rate Time: immediate; paired readingDescription: Comparison of rPPG heart rate results obtained on a given patient on serial readings within 2 minutes of each other.
Measure: Reproducibility of rPPG heart rate readings Time: 2-5 minutesDescription: Comparison of rPPG oxygen saturation results obtained on a given patient on serial readings within 2 minutes of each other.
Measure: Reproducibility of rPPG oxygen saturation readings Time: 2-5 minutesDescription: Comparison of rPPG respiratory rate results obtained on a given patient on serial readings within 2 minutes of each other.
Measure: Reproducibility of rPPG respiratory rate readings Time: 2-5 minutesDescription: Analysis of accuracy of rPPG vital sign readings when stratified by oxygen saturation per conventional monitors stratified as follows: 95-100%; 90-94%; 85-89%; Less than 85%
Measure: Accuracy of rPPG readings by oxygen saturation level Time: immediate; stratified analysisDescription: Analysis of accuracy of rPPG vital sign readings when stratified by skin colour per the Fitzpatrick scale
Measure: Accuracy of rPPG readings by skin colour Time: immediate; stratified analysisDescription: Analysis of accuracy of rPPG vital sign readings when stratified for gender
Measure: Accuracy of rPPG readings by gender Time: immediate; stratified analysisDescription: Analysis of accuracy of rPPG vital sign readings when stratified by age group
Measure: Accuracy of rPPG readings by age Time: immediate; stratified analysisDescription: Analysis of accuracy of rPPG vital sign readings when stratified for COVID, respiratory conditions, cardiac conditions and vascular conditions.
Measure: Accuracy of rPPG readings by comorbidity Time: immediate; stratified analysisFiberoptic bronchoscopy (FOB) is widely used as a diagnostic or therapeutic procedure in intensive care units. Patients with ARDS or COVID-19 disease often undergoes to these procedures. However, intensive care patients might suffer from serious side effects such as prolonged oxygen desaturation and adverse change in lung compliance and resistance. This study aims to evaluate these changes and determine their impact on patient stability.
Description: The variation of regional compliance, calculated by electrical impedance
Measure: Regional Compliance Variation Time: From FOB/BAL to 6 hours laterDescription: The variation of regional resistance, calculated by electrical impedance
Measure: Regional Resistance Variation Time: From FOB/BAL to 6 hours laterDescription: Relation between regional compliance variation and FOB duration
Measure: Regional Compliance and FOB duration Time: From FOB/BAL to 6 hours laterDescription: Relation between regional compliance variation and PaO2 variation
Measure: Regional Compliance and PaO2 Time: From FOB/BAL to 6 hours laterDescription: Relation between atelectasis impedance-detected areas and BAL flooded impedance-detected areas
Measure: Atelectasis areas and BAL flooded areas Time: From FOB/BAL to 6 hours laterDescription: Variation of PaO2 and PaO2/FiO2 ratio post FOB/BAL
Measure: PaO2 and PaO2/FiO2 ratio Time: From FOB/BAL to 6 hours laterDescription: Variation of PaCO2 post FOB/BAL
Measure: PaCO2 Time: From FOB/BAL to 6 hours laterDescription: Relation between the endotracheal tube/fiberscope size ratio and gas exchanges
Measure: Endotracheal tube size and Fiberscope size Time: From FOB/BAL to 6 hours laterDescription: Heart rate (HR), Blood Pressure (BP)
Measure: Hemodynamic variations Time: From FOB/BAL to 6 hours laterAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports